Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm

Leuk Lymphoma. 2022 Jul;63(7):1762-1764. doi: 10.1080/10428194.2022.2042685. Epub 2022 Feb 24.

Affiliations

¹ Pharmacy Service, Hospital de Valme, Sevilla, Spain.
² Hematology Service, Hospital de Valme, Sevilla, Spain.
³ Hematology Service, Hospital Virgen del Rocío, Sevilla, Spain.

PMID: 35200083
DOI: 10.1080/10428194.2022.2042685

No abstract available

Publication types

Letter

MeSH terms

Dendritic Cells
Hematologic Neoplasms* / diagnosis
Hematologic Neoplasms* / drug therapy
Humans
Interleukin-3 Receptor alpha Subunit
Myeloproliferative Disorders*
Recombinant Fusion Proteins
Skin Neoplasms* / diagnosis
Skin Neoplasms* / drug therapy

Substances

Interleukin-3 Receptor alpha Subunit
Recombinant Fusion Proteins
tagraxofusp